keyword
MENU ▼
Read by QxMD icon Read
search

Spiriva

keyword
https://www.readbyqxmd.com/read/28817781/availability-and-variation-of-publicly-reported-prescription-drug-prices
#1
Jeffrey T Kullgren, Joel E Segel, Timothy A Peterson, A Mark Fendrick, Simone Singh
OBJECTIVES: To examine how often retail prices for prescription drugs are available on state public reporting websites, the variability of these reported prices, and zip code characteristics associated with greater price variation. STUDY DESIGN: Searches of state government-operated websites in Michigan, Missouri, New York, and Pennsylvania for retail prices for Advair Diskus (250/50 fluticasone propionate/salmeterol), Lyrica (pregabalin 50 mg), Nasonex (mometasone 50 mcg nasal spray), Spiriva (tiotropium 18 mcg cp-handihaler), Zetia (ezetimibe 10 mg), atorvastatin 20 mg, and metoprolol 50 mg...
July 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28808948/tiotropium-bromide-in-children-and-adolescents-with-asthma
#2
Hengameh H Raissy, H William Kelly
Evidence is emerging on the use of long-acting muscarinic antagonists (LAMAs) in the management of asthma. Tiotropium bromide (Spiriva(®) Respimat(®)) is the only LAMA approved in children and adolescents. As the use of tiotropium becomes more common in clinical practice, it is necessary to review the existing data to identify patients who may benefit from the addition of this medication to their daily asthma regimen. This review discusses recent evidence on the safety and efficacy of tiotropium bromide in the management of asthma in children and adolescents...
December 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28383865/-spiolto-respimat%C3%A2-tiotropium-olodaterol-fixed-combination-for-therapy-of-chronic-obstructive-pulmonary-disease-copd
#3
REVIEW
D Cataldo
Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway disease that can be prevented and treated. The recommendations for therapy include bronchodilators from two classes (LAMA (Long Acting Muscarinic Antagonists) and LABA (Long Acting Beta2 Agonists)). Spiolto Respimat® is a LAMA/LABA combination therapy and comprises tiotropium (Spiriva®) and olodaterol (a LABA). Clinical studies show that Spiolto Respimat® is able to improve lung function tests (Increased FEV1, decreased hyperinflation and residual volume) and quality of life as compared to tiotropium or olodaterol...
June 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28137488/patient-characteristics-associated-with-poor-inhaler-technique-among-a-cohort-of-patients-with-copd
#4
Anne C Melzer, Bijan J Ghassemieh, Suzanne E Gillespie, Peter K Lindenauer, Mary Ann McBurnie, Richard A Mularski, Edward T Naureckas, William M Vollmer, David H Au
BACKGROUND: Inhaled therapies are the cornerstone of pharmacologic management for COPD. Each device requires a unique series of steps to be most effective, making appropriate instruction in inhaler technique a key part of the management of COPD. OBJECTIVES: Examine characteristics of patients and devices associated with poor technique among patients with COPD. METHODS: Cross-sectional study of subjects with COPD using at least one of: metered dose inhaler, Advair Diskus, Spiriva Handihaler, identified from the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) registry...
February 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/27624069/evaluation-of-abbreviated-impactor-measurements-aim-and-efficient-data-analysis-eda-for-dry-powder-inhalers-dpis-against-the-full-resolution-next-generation-impactor-ngi
#5
Megha Mohan, Sau Lee, Changning Guo, S Prasad Peri, William H Doub
The full-resolution next generation impactor (NGI) and three abbreviated impactor systems were used to obtain the apparent aerodynamic particle size distribution (APSD) and other quality measures for marketed dry powder inhalers (DPIs) using the compendial method and efficient data analysis (EDA). APSD for the active pharmaceutical ingredient (API) in Spiriva(®) Handihaler(®), Foradil(®) Aerolizer(®), and Relenza(®) Diskhaler(®) was obtained using a full-resolution NGI at 39, 60, and 90 L/min, respectively...
September 13, 2016: AAPS PharmSciTech
https://www.readbyqxmd.com/read/27470430/pharmacokinetic-bioequivalence-of-two-inhaled-tiotropium-bromide-formulations-in-healthy-volunteers
#6
RANDOMIZED CONTROLLED TRIAL
Jaime Algorta, Laura Andrade, Marta Medina, Valentin Kirkov, Sacha Arsova, Fumin Li, Jingduan Chi
BACKGROUND AND OBJECTIVE: A novel tiotropium bromide monodose capsule dry powder inhaler (DPI) formulation and device have been developed. The formulation was based on a spray-dried matrix that enhances the aerosolizaton properties, allowing a less active tiotropium metered dose (13 µg/capsule) while maintaining the same delivered dose (10 µg/actuation). This study describes the pharmacokinetic bioequivalence to the reference product. METHODS: This randomized, two-stage, crossover, semi-replicate (three-way) study was performed in healthy volunteers...
September 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27354818/cost-effectiveness-of-tiotropium-versus-glycopyrronium-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-in-canada-spain-sweden-and-the-uk
#7
Oskar Eklund, Faraz Afzal, Fredrik Borgström, Jason Flavin, Andrew Ternouth, Maria Eugenia Ojanguren, Carlos Crespo, Mike Baldwin
OBJECTIVES: Tiotropium (TIO), Spiriva® Handihaler®, is a well-established bronchodilator, LAMA (long acting muscarinic antagonist), for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence from the SPARK trial suggests that TIO is superior to glycopyrronium (GLY), Seebri® Breezhaler®, in terms of severe exacerbations. This modeling study assessed the cost-effectiveness of TIO versus GLY for Canada (CAN), Spain (ESP), Sweden (SWE), and the UK, making use of this new clinical evidence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27298519/autocrine-acetylcholine-induced-by-il-17a-via-nf%C3%AE%C2%BAb-and-erk1-2-pathway-activation-promotes-muc5ac-and-il-8-synthesis-in-bronchial-epithelial-cells
#8
Angela Marina Montalbano, Giusy Daniela Albano, Anna Bonanno, Loredana Riccobono, Caterina Di Sano, Maria Ferraro, Liboria Siena, Giulia Anzalone, Rosalia Gagliardo, Michael Paul Pieper, Mark Gjomarkaj, Mirella Profita
IL-17A is overexpressed in the lung during acute neutrophilic inflammation. Acetylcholine (ACh) increases IL-8 and Muc5AC production in airway epithelial cells. We aimed to characterize the involvement of nonneuronal components of cholinergic system on IL-8 and Muc5AC production in bronchial epithelial cells stimulated with IL-17A. Bronchial epithelial cells were stimulated with recombinant human IL-17A (rhIL-17A) to evaluate the ChAT expression, the ACh binding and production, the IL-8 release, and the Muc5AC production...
2016: Mediators of Inflammation
https://www.readbyqxmd.com/read/27255092/therapeutic-error-calls-among-older-adults-reported-to-a-regional-poison-control-center-in-alabama
#9
Sophie Willis, Ann Slattery, William King, Kimberley Benner
OBJECTIVES: Although Americans aged 65 years and older account for only 13.0% of the population, they consume one-third of all prescription medications each year. Increased life expectancy, age-related deterioration in health, and polypharmacy lead to a significant risk of potential medication errors. National Poison Data System studies have evaluated the older adult population and their interaction with poison centers; however, descriptive studies using regional poison center data to evaluate older adult-related medication errors, specifically in Alabama, have not been conducted...
June 2016: Southern Medical Journal
https://www.readbyqxmd.com/read/27173989/comparison-of-aerodynamic-particle-size-distribution-between-a-next-generation-impactor-and-a-cascade-impactor-at-a-range-of-flow-rates
#10
Hiroyuki Yoshida, Akemi Kuwana, Hiroko Shibata, Ken-Ichi Izutsu, Yukihiro Goda
Wide variation in respiratory flow rates between patients emphasizes the importance of evaluating the aerodynamic particle size distribution (APSD) of dry powder inhaler (DPI) using a multi-stage impactor at different flow rates. US Pharmacopeia recently listed modified configurations of the Andersen cascade impactor (ACI) and new sets of cut-off diameter specifications for the operation at flow rates of 60 and 90 L/min. The purpose of this study was to clarify the effect of these changes on the APSD of DPI products at varied flow rates...
April 2017: AAPS PharmSciTech
https://www.readbyqxmd.com/read/27038884/il-17a-induces-chromatin-remodeling-promoting-il-8-release-in-bronchial-epithelial-cells-effect-of-tiotropium
#11
Giulia Anzalone, Rosalia Gagliardo, Fabio Bucchieri, Giusy Daniela Albano, Liboria Siena, Angela Marina Montalbano, Anna Bonanno, Loredana Riccobono, Michael Paul Pieper, Mark Gjomarkaj, Mirella Profita
AIMS: IL-17A plays a key role in the persistence of airway inflammation, oxidative stress, and reduction of steroid-sensitivity in COPD. We studied the effect of IL-17A on chromatin remodeling and IL-8 production. MAIN METHODS: We measured the levels of IL-8 and IL-17A in induced sputum supernatants (ISS) from healthy controls (HCs), healthy smokers (HSs), and COPD patients by enzyme-linked immunosorbent assay (ELISA). A human bronchial epithelial cell line (16HBE) was stimulated with ISS from HCs, HSs, or COPD subjects...
May 1, 2016: Life Sciences
https://www.readbyqxmd.com/read/27013907/investigation-of-the-efficacy-of-generic-and-brand-name-tiotropium-bromide-in-the-management-of-chronic-obstructive-pulmonary-disease-a-randomized-comparative-trial
#12
Yunes Panahi, Mostafa Ghanei, Mohammad Behzadi, Maryam Salehi, Sara Saffar Soflaei, Amirhossein Sahebkar
INTRODUCTION: The beneficial effects of tiotropium bromide, a long acting anticholinergic bronchodilator, in the management of chronic obstructive pulmonary disease have been shown in previous studies. The present study aimed to compare the efficacy and safety of generic (Tiova®) and brand-name (Spiriva®) tiotropium preparations in patients with COPD. METHODS AND MATERIALS: In this randomized double-blind parallel-group trial, 79 patients with documented COPD were assigned to Tiova® or Spiriva® for a period of 4 weeks...
March 2016: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/27013871/a-cross-sectional-study-to-assess-inhalation-device-handling-and-patient-satisfaction-in-copd
#13
Marc Miravitlles, Jéssica Montero-Caballero, Frank Richard, Salud Santos, Juan Luis Garcia-Rivero, Francisco Ortega, Xavier Ribera
Delivery of inhaled medications via an inhaler device underpins the effectiveness of treatment for patients with chronic obstructive pulmonary disease (COPD). Correct inhaler technique among patients is also a predictor of achieving treatment compliance and adherence. Reporting of patient satisfaction with inhalers is therefore gaining increasing attention and is now recognized as an important patient-reported outcome in clinical trials involving patients with COPD or asthma. In this cross-sectional study, we use the validated Patient Satisfaction and Preference Questionnaire (PASAPQ) to assess the handling and satisfaction for Respimat(®) Soft Mist™ Inhaler (SMI) compared with the Breezhaler(®) dry powder inhaler (DPI) among patients with COPD in Spain...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/26650145/tiotropium-respimat-is-effective-for-the-treatment-of-asthma-at-a-dose-lower-than-that-for-chronic-obstructive-pulmonary-disease
#14
Stacy J Chin, Anthony G Durmowicz, Badrul A Chowdhury
Anticholinergic drug products are not part of the current treatment paradigm for asthma, despite their widespread availability for chronic obstructive pulmonary disease (COPD) and interest in their use for asthma. Published study results, mostly of short duration and primarily with ipratropium and tiotropium, have revealed inconsistent efficacy results. Consequently, the role of inhaled anticholinergic drugs in the treatment of asthma has been unclear. This commentary discusses and comments on data from five clinical trials in adults that were submitted by Boehringer Ingelheim to the U...
February 2016: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/26532804/the-potential-societal-cost-benefits-of-increasing-patient-satisfaction-by-using-an-inhaler-with-improved-features-compared-to-spiriva%C3%A2-handihaler%C3%A2-for-the-management-of-chronic-obstructive-pulmonary-disease-copd-in-the-uk
#15
J L Nicolai, S Torvinen, U Comberiati, R Miles, M H Greaney, D J Howard, A Plich
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26532790/the-budget-impact-of-an-inhaler-with-improved-features-compared-to-spiriva%C3%A2-handihaler%C3%A2-for-the-management-of-chronic-obstructive-pulmonary-disease-copd-in-the-uk-estimated-impact-on-unscheduled-healthcare-costs-and-inhaler-satisfaction
#16
J Nicolai, S Torvinen, D J Howard, R Miles, M H Greaney, U Comberiati, A Plich
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26358316/tiotropium-%C3%A2-what-role-in-asthma
#17
(no author information available yet)
Tiotropium solution for inhalation (Spiriva Respimat - Boehringer Ingelheim) is the first long-acting muscarinic antagonist to be marketed in the UK for the management of asthma. It is licensed as add-on maintenance bronchodilator treatment in adults with asthma who are using an inhaled corticosteroid (≥800μg budesonide/day or equivalent) and a long-acting beta2 agonist, and who have had one or more severe exacerbations in the previous year. This corresponds to use at step 4 of both the British asthma guideline and the Global Initiative for Asthma (GINA) strategy for the treatment of asthma in adults...
September 2015: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/26324401/cost-effectiveness-of-glycopyrronium-bromide-compared-with-tiotropium-in-patients-with-chronic-obstructive-pulmonary-disease-in-sweden
#18
COMPARATIVE STUDY
Madlaina Costa-Scharplatz, Björn Ställberg, Pankaj Goyal, Yumi Asukai, Jean-Bernard Gruenberger, David Price
OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting. METHODS: A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations...
December 2015: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/26201967/de-agglomeration-effect-of-the-us-pharmacopeia-and-alberta-throats-on-carrier-based-powders-in-commercial-inhalation-products
#19
Sharon Shui Yee Leung, Patricia Tang, Qi Tony Zhou, Zhenbo Tong, Cassandra Leung, Janwit Decharaksa, Runyu Yang, Hak-Kim Chan
The US pharmacopeia (USP) and Alberta throats were recently reported to cause further de-agglomeration of carrier-free powders emitted from some dry powder inhalers (DPIs). This study assessed if they have similar influences on commercially available carrier-based DPIs. A straight tube, a USP throat, and an Alberta throat (non-coated and coated) were used for cascade impaction testing. Aerosol fine particle fraction (FPF ≤ 5 μm) was computed to evaluate throat-induced de-agglomeration. Computational fluid dynamics are employed to simulate airflow patterns and particle trajectories inside the USP and Alberta throats...
November 2015: AAPS Journal
https://www.readbyqxmd.com/read/25853581/spiriva-respimat-an-oral-inhalation-spray-for-copd
#20
(no author information available yet)
No abstract text is available yet for this article.
March 30, 2015: Medical Letter on Drugs and Therapeutics
keyword
keyword
53557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"